{"type":"trials","record":{"id":41643,"source_id":"clinicaltrials-gov","external_id":"NCT07338513","title":"User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems","brief_summary":"Age-Related Macular Degeneration (AMD) is the leading cause of central vision loss among older adults worldwide. Patients with AMD often require frequent monitoring of visual function and disease progression, typically through multiple follow-up visits involving optical coherence tomography (OCT), visual acuity testing (VA), and clinical consultations. While digital self-monitoring tools have emerged as promising solutions to reduce the burden of in-clinic visits, many elderly patients face challenges in engaging with these platforms due to visual impairment, limited digital literacy, and poorly optimised user interfaces. These barriers may reduce patient willingness to adopt such systems and undermine their long-term effectiveness. To address this gap, the study team has developed the web-based AVIGA (Automated Vision Impairment Gaze-tracking Analysis) system, which is a portable, self-administered, home-based digital monitoring system designed to minimise cognitive load and maximise usability for elderly AMD patients. The platform integrates patient-centred design principles such as simplified navigation, optimised text, and multimodal feedback (visual and audio) to empower users to independently track their visual health. A prospective, single-site usability trial to evaluate the AVIGA platform using validated human factors measures: the System Usability Scale (SUS), the Technology Acceptance Model (TAM) will be conducted. By examining the relationship between usability, cognitive load, and perceived empowerment, this study aims to identify critical user interface and user experience (UI/UX) design factors that influence willingness to adopt and sustain use of digital health tools among elderly AMD patients.","overall_status":"Not Yet Recruiting","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Tan Tock Seng Hospital","enrollment":30,"countries":["Singapore"],"start_date":"2026-01-01","completion_date":"2027-09-01","last_update_date":"2026-01-14","source_url":"https://clinicaltrials.gov/study/NCT07338513","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Not Yet Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"AVIGA-SURVEY","age_range":"55 Years to 99 Years","comparator":null,"organization":"Tan Tock Seng Hospital","interventions":[],"registry_source":"ClinicalTrials.gov","outcome_measures":["Assess System Usability — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±3…","Assess System Acceptance — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±…","Track Change Over Time — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±3…"],"design_description":null,"source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Wet Age-related Macular Degeneration"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07338513","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-01-01 to 2027-09-01","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years to 99 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.846Z","intervention":[],"participants":30,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Assess System Usability — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±3…","Assess System Acceptance — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±…","Track Change Over Time — Baseline, Mid-point (6 months from baseline ±3 months), End-point (12 months from baseline ±3…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: aging, age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41643","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}